Strengthened by improved clinical trial designs, two additional PMO‐based ASOs have recently been approved for DMD patients amenable for dystrophin exon 53 skipping, i.e. golodirsen and viltolarsen, by the FDA, and both the FDA and Japanese Ministry of Health Labour and Welfare, respectively (Dhillon, 2020; Heo, 2020). This evidence concerns the gene DMD and Duchenne muscular dystrophy.